Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
暂无分享,去创建一个
K. Alexander | L. Newby | W. Gibler | E. Ohman | E. Peterson | M. Roe | C. Gibson | C. Pollack | E Magnus Ohman | L Kristin Newby | Eric D Peterson | C Michael Gibson | W Brian Gibler | Matthew T Roe | Karen P Alexander | A. Chen | Anita Y Chen | Nancy M. Allen-LaPointe | Nancy M Allen-LaPointe | Charles Pollack | C. Gibson
[1] W Klein,et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.
[2] T. Brennan,et al. Incidence and types of preventable adverse events in elderly patients: population based review of medical records , 2000, BMJ : British Medical Journal.
[3] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[4] Deepak L. Bhatt,et al. Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .
[5] S. Zeger,et al. Longitudinal data analysis using generalized linear models , 1986 .
[6] P. Pezzotti,et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. , 2000, JAMA.
[7] Robert H Christenson,et al. Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[8] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[9] D. Mungall,et al. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. , 1997, Archives of internal medicine.
[10] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[11] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[12] A. Siegbahn,et al. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. , 1999, Lancet.
[13] P. Ridker,et al. Use and effectiveness of intravenous heparin therapy for treatment of acute myocardial infarction in the elderly. , 1998, Journal of the American College of Cardiology.
[14] W. Pagel. Paracelsus: An Introduction to Philosophical Medicine in the Era of the Renaissance , 1958 .
[15] P J Schneider,et al. ASHP national survey of pharmacy practice in acute care settings: dispensing and administration--1999. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] S. Yusuf,et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis , 2000, The Lancet.
[17] C. Giaquinto,et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. , 2006, AIDS.
[18] M. Dalby,et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. , 2003, Journal of the American College of Cardiology.
[19] Alastair Baker,et al. Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.
[20] Marvin C. Alkin,et al. What Have We Learned? , 2019, Stumbling Blocks Against Unification.
[21] H. E. Gerber. Five years after , 2010, Nature Genetics.
[22] E. Topol,et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). , 2005, The American journal of cardiology.
[23] E. Rosenberg,et al. Primary HIV type 1 infection. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] R. Califf,et al. Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience , 2002 .
[25] R. Califf,et al. Changing the model of care for patients with acute coronary syndromes. , 2003, American heart journal.
[26] Vivian Nutton,et al. Paracelsus. An introduction to philosophical medicine in the era of the Renaissance , 1983, Medical History.
[27] Joshua Borus,et al. Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.
[28] Paul J. Williams,et al. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. , 2004, Clinical therapeutics.
[29] P. Pronovost,et al. Five years after to err is human , 2005 .
[31] L. Wallentin,et al. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.
[32] E. Antman,et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. , 2002, American heart journal.
[33] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[34] L. Magder,et al. Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group. , 2000, The Pediatric infectious disease journal.
[35] E. Antman,et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. , 2003, American heart journal.
[36] R. Califf,et al. Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. , 2005, JAMA.
[37] G. Burtless,et al. Five Years After , 1949 .
[38] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.
[39] Deepak L. Bhatt,et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, JAMA.
[40] C. Rouzioux,et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] D. Bates,et al. Effects of computerized physician order entry on prescribing practices. , 2000, Archives of internal medicine.
[42] C. Cannon. Thrombolysis medication errors: benefits of bolus thrombolytic agents. , 2000, The American journal of cardiology.
[43] D. Young,et al. Blood transfusion costs by diagnosis‐related groupsin 60 university hospitals in 1995 , 2001, Transfusion.
[44] Y. Maldonado,et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. , 2005, JAMA.
[45] Sunil V. Rao,et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.
[46] R. Califf,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.